

ABSTRACT

Anti-PD-1 and Mutant IL-2 Immunoconjugate Formulation

The present invention relates to formulations comprising an immunoconjugate of a recombinant anti-programmed death receptor 1 (PD-1) antibody and a mutant interleukin-2 (IL-2) (also referred to as " α PD-1/IL2m"), particularly stable liquid formulations, as well as methods for preparing said formulations, and the use of said formulations for the treatment and/or prevention of diseases.

[No suitable figure]